Table 2.
Preclinical studies that used intratracheal instillation for delivering SC-Exos.
| Disease | Source of Exosomes |
Instilled Dose | Animal Model | Refs |
|---|---|---|---|---|
| Severe steroid-resistant asthma (SSRA) | Human UCMSCs |
100 μg Exos in 50 μL Phosphate-buffered saline (PBS) | Ovalbumin (OVA)/: (complete Freud’s adjuvant) CFA-induced SSRA mice | [89] |
| Ischemia/reperfusion (I/R) injury | Murine BMSC | Exos derived from 2 × 106 in 30 μL PBS | I/R model mice | [97] |
| Cigarette smoke (CS)-induced lung injury |
Human ASC | 30 μL of purified Exos solution (as explained in the original paper) | CS-exposed C57BL/6 mice | [95] |
| ARDS | BMSC | 50 mg Exos in 10 mL PBS and 100 mg Exos in 10 mL PBS | LPS-induced ARDS C57BL/6 mice | [46] |
| Phosgene-induced acute lung injury (ALI) | Rat BMSC | Exos isolated from 3 × 106 MSC (50 mL) | Phosgene-induced ALI Sprague–Dawley rat | [108] |